Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases. January, 2019
|
|
- Elijah Johnson
- 5 years ago
- Views:
Transcription
1 Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases January, 2019
2 Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii) regulatory authorities will agree with the Company s further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company s activities, perspectives, financial situation, results and development. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ( Facteurs de Risques ) section of the Document de Référence, available on the AMF website ( or on Transgene s website ( Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forwardlooking statements, even if new information becomes available in the future. 2
3 Focused on enhancing our leadership in viral vector-based immunotherapies Mature Clinical Assets Early-Stage Clinical Assets Technology Platforms TG4010 TG4001 TG6002 Pexa-Vec TG1050 First candidates in clinic in
4 World leader in viral-vector based immunotherapies Experience driven innovation Clinical pipeline Our new cutting edge technology platforms THERAPEUTIC VACCINES ONCOLYTIC VIRUSES TG 4010 TG 4001 TG 1050 PEXA-VEC TG6002 Informed decisions WORLD LEADING SCIENCE First candidates in clinic in
5 Broad pipeline of clinical-stage immunotherapies Transgene strategic trials are poised to deliver key read out in 2019 Product THERAPEUTIC VACCINES Indication Preclinical Clinical Phase Phase 1 Phase 2 Phase 3 Next Key Milestone TG4010 TG4001 Non-small cell lung cancer 1 st line Recurrent HPV-positive head and neck cancers + nivolumab (ICI) + CT + avelumab (ICI) 2H 2019: ORR (35 patients) 2H 2019: First efficacy date TG1050 Chronic hepatitis B Potential partnership + antiviral ** * * ONCOLYTIC VIRUSES Pexa-Vec Advanced HCC 1 st line (PHOCUS) Advanced HCC 1 st line + sorafenib + nivolumab (ICI) 2H 2019: Intermediary readout Mid 2019: ORR (15 patients) TG6002 Colorectal cancer ** TBC *** * Clinical collaboration / ** Rights acquired for Greater China ***Transgene has commercial rights to Pexa-Vec in Europe and additional selected countries. 5
6 Therapeutic Vaccines Pioneering virus-based immunotherapeutics
7 Lung cancer Better therapeutic options still needed for non-responders (ICIs) Most patients still diagnosed at late stages, with dismal prognosis Need to increase response rate and OS Non-small cell lung cancer First-line therapy Min. 350 K patients * 30 % of 1L patients whose tumor cells express high levels of PD-L1 ( 50 %) Pembrolizumab registered since % of 1L patients whose tumor cells express no or low levels of PD-L1 (<50 %) Pembrolizumab registered in combination with pemetrexed / carboplatin CT since 2017 (USA) and 2018 (EU) Still a major unmet need as a majority of patients do not respond to ICIs *Source: USA, EU, JP, Globocan, Company estimates 7
8 TG4010 Compelling lung cancer clinical data Improved response rate & duration of response SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS) TG4010 in combination with chemotherapy for 1 st line NSCLC TG chemotherapy 40.9 [ ] wks Non-squamous (n) ORR Median duration of response (wks) TG CT 98 40% 41 Placebo + CT 98 28% 18 Chemotherapy (n=27) 18.1 [ ] wks Placebo + chemotherapy 18.1 [ ] wks Improved response rate & duration of response Good safety profile Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 8
9 TG4010 Compelling lung cancer clinical data Well positioned for further development in NSCLC SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS) TG4010 in combination with chemotherapy for 1 st line NSCLC Progression-free survival (months) Patients with non sq. tumors (n=196) Overall survival (months) Patients with non sq. tumors (n=196) Significant improvements in PFS and OS in patients in patients with non sq. tumors TG chemotherapy Placebo + chemotherapy 35% 19% TG chemotherapy Placebo + chemotherapy 36% 20% Clinical efficacy in both PD-L1 negative and PD-L1 positive patients Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 9
10 TG4010 1L To increase ORR with triple combination regimen in patients with non sq. NSCLC expressing low levels of PD-L1 (<50%) Study Proof-of-concept Phase 2 trial Collaborative agreement with BMS (supply of nivolumab) First patient treated in January 2018 Recruitment to be completed in 2Q 2019 Primary endpoint evaluation expected in 2H 2019 (ORR on 35 patients) Endpoints Primary endpoint: objective response rate (ORR) Secondary endpoints: duration of response, disease control rate, progression-free survival (PFS), overall survival (OS), and safety Protocol Up to 39 patients (35 evaluable patients) Multi-center, single-arm, open label study First-line treatment, stage IIIB-IV or delayed relapse, non sq. NSCLC with low or undetectable PD-L1 expression (<50%) Study regimen TG PFU weekly for 6 weeks then every 3 weeks by SC route Nivolumab 360 mg every 3 weeks by IV route Pemetrexed-carboplatin (or cisplatin) every 3 weeks for 4 cycles followed by pemetrexed maintenance Participating countries USA Belgium Denmark France 10
11 TG4001 HPV-positive Head & Neck Cancers (HNSCC) Phase 1b/2 in combination with avelumab (Bavencio ) MVA encoding for HPV16 E6 & E7 and IL-2 In collaboration with Principal Investigator Pr Christophe Le Tourneau, Institut Curie Protocol Up to 50 patients (France) Multi-center, single-arm, open label trial Metastatic or refractory/recurrent HPV-16+ head & neck cancer, after failure of standard therapy Endpoints (Phase 2 part) Primary endpoint: Objective response rate (ORR) Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response and safety First patient treated in September 2017 Following positive safety evaluation, Phase 2 part ongoing and additional sites being activated Phase 1 results in 4Q 2018 (n=9 patients) Next clinical readout expected in 2H
12 TG1050 Positive Phase 1 results (safety and immunogenicity) Adeno encoding for 3 HBV antigens Phase 1 results presented at AASLD 2018 (n=48 patients) Principal investigator Prof Fabien Zoulim, Hospices civils, Lyon (France) Participating countries: Canada, France, Germany Protocol Up to 48 patients Randomized safety and dose-finding study Patients currently being treated with SoC antiviral therapy Rights for Greater China acquired by Tasly Pharmaceuticals (July 2018) Primary endpoint met: good safety profile confirmed TG1050 triggers T cell-based immune responses, specific of all 3 encoded HBV antigens Intermediate dose (10 10 vp) consistently immunogenic ( 70% of patients) New preclinical data support further investigation in combination with antivirals and immunomodulators 12
13 TG1050 Key findings of the positive Phase 1 trial Safety: Clinical trial primary end-point reached. Subcutaneous SD & MD injections of TG1050 in NUC-suppressed CHB patients is well tolerated over the 3 DLs. No negative impact on disease control, especially in the sensitive part of patients with no pre-immunity against the adenoviral vector, reinforces the robust safety profile of TG1050. Immunogenicity: TG1050 induces HBV-specific cellular immunity (IFN-g cells) in NUC-suppressed CHB patients without or with low anti-ad5 pre-immunity. 0 Induced responses are specific of single or multiple antigens expressed by TG1050 (Core/Pol & Env). Detection of Env-specific responses is encouraging in a highly tolerogenic context for this antigen. Responses are detected following single and multiple injections: Intermediate dose vp is consistently immunogenic (~70% of patients). HBsAg evolution: HBsAg decline reaches 0.4 log over time in 2 patients of vp group. Number of patients with low anti-ad5 preimmunity per dose group responding to at least 1, 2 or 3 antigens Heatmap of ELISpot responses. Patients with low anti-ad5 pre-immunity are listed as lines and test conditions as columns Individual evolution of ELISpot responses over time in patients with low anti-ad5 pre-immunity Detectable responses in both SD & MD cohorts at & vp doses ; Env-specific responses detected despite TG1050 encoding for only small domains of Env/HBsAg as well as the very high tolerance against HBsAg characterizing CHB carriers.
14 Entering the field of individualized immunotherapies using our unique proven MVA based platform
15 myvac TM Individualized immunotherapy platform Targets patients neoantigens Immunotherapy Safety Efficacy MVA-based therapeutic vaccine Therapeutic class with established track-record Proven anti-tumor activity The advantages of personalised treatment without the drawbacks of autologous approaches Individualized One cancer, One patient, One vaccine Flexible Versatile platform and AI integration Clinical First trials will start in
16 myvac TM Transgene s vaccine expertise provides the insights needed to leverage multiple cutting edge technologies Artificial Intelligence Gene editing Genome sequencing 16
17 myvac TM Targeting unique patient specific set of mutations Because of deficient repair mechanisms and rapid proliferation, tumor cells accumulate DNA mutations Some mutations lead to the generation of non-self proteins (therefore immunogenic) These neoantigens are more immunogenic than classical tumor associated antigens Transgene s myvac vaccines against neoantigens are expected to induce broader and stronger T cell responses 17
18 myvac network combines bioengineering & digital transformation Identify patients eligible for individualized immunotherapies Secure and exploit genomic data Select the most relevant neo-antigens Manufacture myvac product in controlled time and cost Realize clinical proof of concept 100 Percent survival 50 Vaccin Placebo Time (days) World renown US and UK clinical centers 18
19 Clinical protocols being finalized with 2 international KOLs Dr Christian Ottensmeier presenting at SITC 2018 HPV negative head and neck cancers After surgery and adjuvant therapy Ovarian cancer After surgery and adjuvant chemotherapy Trials are expected to start in 2019 (Europe & USA) 19
20 Oncolytic Viruses Pioneered by Transgene A new and highly promising therapeutic class in the fight against cancer. Transgene leading the development of multifunctional OVs for the enhanced modulation of the TME via a single therapeutic.
21 Pexa-Vec Lead oncolytic virus Transgene owns development and commercialization rights in Europe Licensor: SillaJen (KOSDAQ: ) HCC 1L Global Phase 3 trial Combination Phase 2 trial conducted by Transgene Global clinical development plan Other solid tumors Exploratory Phase 2 trials conducted by Transgene Exploratory Phase 1 trials led by SillaJen (RCC 2L, CRC 2L/3L) 21
22 Pexa-Vec Large unmet medical need in HCC Dismal prognosis Better therapeutic options needed 25,000 eligible patients in Europe* First-line therapy Sorafenib - modest activity ORR: 2% ; median OS: 10.7 months Lenvatinib recently approved with non-inferiority results (USA, EU, Japan) Nivolumab could become a new therapeutic option: Promising activity in Phase 3 (still ongoing) Second-line therapy Regorafenib ORR: 10%; median OS: 10.6 months Nivolumab approved by FDA (2017) ORR: 18%; median OS: 15.6 months Pembrolizumab approved by FDA (2018) ORR: 17%, median OS: 12.9 months * Source: Globocan, Company estimates 22
23 Pexa-Vec Key Phase 2 clinical trial results Clinical activity demonstrated in multiple trials Trials with >300 patients treated with Pexa-Vec in variety of tumor types, including liver, colorectal and kidney Proof of concept for MOA: active immunotherapy 30-patient dose-finding Phase 2 trial in HCC (80% of patients first-line) OS results - high dose versus low dose Median OS: 14.1 (high dose) vs. 6.7 months (low dose) Hazard Ratio = 0.39 p = Nature Medicine, Volume 19, Issue 2, February
24 Pexa-Vec Triggers antitumor immunity after single IV administration Prior to planned surgery of locally advanced, poor prognosis or metastatic cancers Pexa-Vec shown to Selectively target tumor tissue after single IV administration Stimulate the adaptive and innate anti-tumor immune response Induce expression of PD-L1 and PD-1 pathways Single IV Pexa-Vec Surgery Post-surgery d1 d2 d3 d5 d14 ± 4d 1m 3m Peripheral blood samples collected n = 8 ; 3 with metastatic melanoma and 5 with colorectal cancer metastases to the liver (CRLM) One complete and one partial tumor pathological response at the time of surgery on four evaluable CRLM patients Presence of Pexa-Vec in tumor tissue Normal tissue Tumor-specific adaptive T cell responses (T cell Elispot) Patient : Mel. CRLM TAA : MART1 CEA Preinfusion PBMCs exhibited robust activation by 24 hrs post-infusion Expression of CD69 (an early activation marker) was enhanced on effector cell populations, notably NK & T cells Expression of PD-L1 was increased CD69 PD-L1 CRLM tissue showing expression of Pexa-Vec, signs of inflammation and fibrosis, necrotic cells 1 month postinfusion Data support ongoing development of Transgene s Vaccinia virus-based oncolytics Source: Samson, A. et al, Single intravenous preoperative administration of the oncolytic vaccinia virus Pexa-Vec to prime anti-tumor immunity, ASCO 2018, June
25 Pexa-Vec Clinical development plan in HCC - 1 st line Pivotal Phase 3 and combination Phase 2 Position Pexa-Vec with current and future standard of care Advanced HCC 1 st line Phase 3 Pexa-Vec + sorafenib Conducted by Advanced HCC 1 st line Phase 1/2 Pexa-Vec + Opdivo (nivolumab) Conducted by Multi-center Phase 3 trial in Europe, USA, Asia Randomized, two-arm trial Ongoing global recruitment First patient included in China in Sept First data (efficacy vs SoC) expected in 2019 Multi-center Phase 1/2 trial in France, Italy, USA Open-label, single-arm trial Safety review committee expected before year-end 2018 Interim analysis (15 patients) expected mid-2019 (primary endpoint ORR) 25
26 Next Generation of Oncolytic Viruses Transgene s novel Oncolytic Viruses are based on its optimal Vaccinia virus backbone armed with either chemo or immuno payloads
27 Oncolytic viruses Three complementary ways to act on the tumor Oncolysis Specific replication in tumor cells, and direct lysis of infected cells Immune response Induction of immunogenic cell death, engagement of both innate and adaptive anti-tumor immunity Many routes to reach the tumor (i.e. IV, IT) Immuno-modulating payloads delivery Targeted delivery of anti-tumor modalities, synergistic with other MOAs (e.g. targeted CT, or immune modulation of TME) 27
28 Vaccinia virus (VV) The optimal oncolytic backbone Excellent Oncolytic activity of the Copenhagen vaccinia strain Good immunological balance (Th1 vs Th2, anti-tumor vs antiviral responses, etc.) Large genome capacity (up to 25 kb), to accommodate multiple transgenes Tumor selective replication in numerous cancer cell types, and good safety profile Pure cytoplasmic replication (no risk for genome integration or mutagenesis) Well-established processes for GMP manufacturing 28
29 CAL33 HepG2 HCT116 Hela SK-Mel1 PANC1 A549 Hs746T SKOV3 UMUC3 LoVo SW780 OE21 U87MG MIA PaCa2 OE19 U118MG KATO3 SNU5 OVCAR3 Magnitude of replication % surviving cells VV COP TK-RR- Targets a large spectrum of human tumors Replication 20 tumor cell lines, MOI 10-3, 48 hrs post-infection 10 5 Oncolytic activity 10 cell lines, MOI variable, day 5 post-infection
30 TG6002 Our VV oncolytic backbone enhanced by tumor targeted chemotherapy
31 TG6002 Advanced OV already in the clinic Viral oncolysis + local production of chemotherapy Multiple Advantages: TG Excellent oncolytic properties 2. Highly tumor selective 3. IV delivery 4. Targeted chemotherapy with FCU1 gene - allowing the production of 5-FU in the tumor FCU1 gene Unique and proprietary High 5-FC to 5-FU conversion rate No FCU1 related safety issue Preclinical results confirm potency Greater China rights acquired by Tasly Biopharmaceuticals as part of a $48 million (July 2018) 31
32 TG6002 Significant anti-tumor activity in multiple human cell lines Example: Evaluation of systemic injection of TG6002 in the colorectal cell line (LoVo) P < 0,05 P < 0,005 TG FC Mice: n=12 Similar results with other cell lines: pancreas (MiaPaca2); glioblastoma (U-87MG), esophaegal (OE19), stomach (HS746T), hepatocarcinoma (Hep G2) 32
33 TG6002 In Phase 1/2a GI cancer clinical study Viral oncolysis + local production of chemotherapy administered IV Gastro-intestinal adenocarcinoma with liver metastasis (colon cancer) (Tumors known to be 5-FU sensitive) Protocol Multi-center Phase 1/2a trial Phase 1 part (dose escalation): up to 24 patients Phase 2a part (efficacy): 35 patients Trial will include biodistribution analysis Principal investigator Prof Philippe Cassier, centre Léon Bérard (Lyon, France) Regimen TG6002 IV: D1, D8, D mg/kg/day Oral 5-FC prior to TG6002 Additional cycles until disease progression INDs granted in Belgium, Spain, France First patients recruited in Q Expected Ph 1 Readout: H
34 Our new generation oncolytic products The Invir.IO TM Platform: Immuno-armed Vaccinia Virus (VV)
35 Multiple options for immune modulation of the tumor micro-environment via immuno-armed oncolytic VVs Chemokines Favoring tumor infiltration Undisclosed sdabs Unlocking local immunosuppression Better release of tumor Ags, and of related immunostimulatory molecules hcd Local expansion, and activation of APC and effectors cells Cytokines TNFR-Ls TCEs Agonistic sdabs Degradation of immunosuppressive metabolites and cells in the TME Undisclosed enzyme ICIs Anti-CTLA-4 35
36 OV encoding for anti-ctla-4 mab Improving on validated MoA of ipilimumab Preclinical PoC Building a potent multifunctional OV Transgene s OVs deliver functional mab in the TME (1) BioInvent s full length human recombinant anti-ctla-4 Abs promote depletion of intratumoral Treg cells (2) Improved efficacy compared to combination of separate Ab and OV (1) Longer duration of expression Expected improved tolerability owing to lower systemic antibody exposure in peripheral nontumor compartments Indications: multiple solid cancers In late stage preclinical development (1) Kleinpeter P. et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scfv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition, OncoImmunology, Oct (5:10) (2) Vargas F. et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell, April 2018 (33: 1-15) 36
37 Transgene to deliver multiple valueenhancing clinical data readouts and preclinical milestones in 2019
38 Significant anticipated value-creating news flow Portfolio to deliver news flow in the near-term 1H H 2019 Pexa-Vec + nivo 1L HCC Safety review committee TG4010 1L NSCLC Recruitment completed TG4010 1L NSCLC ORR on 35 patients Pexa-Vec + nivo 1L HCC Interim analysis (ORR) on 15 patients TG6002 Phase 1 clinical readout TG4001 SCCHN First efficacy readout Pexa-Vec Phase 3 1L HCC Futility analysis Pexa-Vec Phase 3 1L HCC Interim analysis 1 st product in clinic 1 st product in clinic Clinical results Clin. trial milestone Next generation platforms 38
39 Company funded to deliver multiple value generating milestones Key figures 26.6 million Cash and cash equivalents as of September 30, 2018 Key shareholders As of December 31, million 25 million Operating revenues as of September 30, 2018 (incl. the sale of the TG1050 rights in China for 35.6 million) Expected cash burn for % Free float 43 % Financial visibility to end September 2019 (excl. the potential monetization of the Tasly Biopharmaceuticals shares - $48 million) Market capitalization: ~ $200 million as of December 31, million shares outstanding million options and restricted stocks Listed on Euronext Paris ISIN: FR Ticker: TNG 39
40 Transgene A world leader in viral-vector based immunotherapies Strong late stage clinical pipeline of therapeutic vaccines multiple value adding milestones expected in 2019 Novel myvac individualised immunotherapy platform results from Transgene s significant clinical vaccine expertise First clinical trials to start in 2019 Well positioned to be a best-in-class in oncolytic viruses via the further development of TG6002 and our Invir.io platform Both are based on our proprietary large capacity VV COP TK-RR- backbone First Invir.io product to enter the clinic in 2019 Adequate financial resources to fund business 40
41 Contact Jean-Philippe Transgene 400 Boulevard Gonthier d Andernach - Parc d Innovation - CS Illkirch Graffenstaden Cedex France Tél.: + 33 (0)
Virus-based immunotherapies to transform the fight against cancers and infectious diseases. September 2018 First Half 2018 & Business Update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases September 2018 First Half 2018 & Business Update Disclaimer This presentation contains forward-looking statements,
More informationVirus-based immunotherapies to transform the fight against solid tumors and infectious diseases. March 2019 Full Year Results 2018 & Business Update
Virus-based immunotherapies to transform the fight against solid tumors and infectious diseases March 2019 Full Year Results 2018 & Business Update Disclaimer This presentation contains forward-looking
More informationVirus-based immunotherapies to transform the fight against cancers and infectious diseases. March 21, 2018 FY Results 2017 & Business update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases March 21, 2018 FY Results 2017 & Business update Disclaimer This presentation contains forward-looking statements,
More informationViral-based immunotherapies to transform the fight against cancers and infectious diseases. November 2017 Corporate Presentation
Viral-based immunotherapies to transform the fight against cancers and infectious diseases November 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, which are
More informationJefferies Healthcare Conference, London, November 19-20, Elisabetta Castelli PhD Director Investor Relations
Jefferies Healthcare Conference, London, November 19-20, 2014 Elisabetta Castelli PhD Director Investor Relations SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the
More informationFirst half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed Seven active clinical trials: o First patients treated in four combination trials
More informationTransgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials Programs progressing in line with strategy Significant reduction of net loss: 12.2 million compared to
More informationTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy
Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy Parc d Innovation, Illkirch, France, March 22, 2010 Transgene (Euronext Paris: FR0005175080) details its
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationTransgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
2017 Full-year results and business update Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses All clinical programs made progress o o 7 clinical
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationTG4010. Public Information
TG4010 Public Information 11 May 2017 Public Information 11 May 2017 Page 2 /7 ABBREVIATIONS DNA Deoxyribonucleic acid GMO Genetically modified organism IL2 Interleukin-2 IM Intramuscular IT Intratumoral
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationEnhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationIdera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals
Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationIMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018
NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More information